Our Mission We discover innovative antibody drugs
to cure rare diseases and save lives
OUR COMPANY
Initium Therapeutics challenges the existing
science and technologies
OUR COMPANY
Initium (genitive initiī) (neut.)

means “beginning” or
“commencement" in Latin
OUR COMPANY
Initium Therapeutics challenges the existing
science and technologies
OUR COMPANY

R&D

What We Do

We make use of diverse antibody discovery
platforms as appropriate for the target.
The technologies we employ in antibody
discovery include Single B cell sequencing
and Hybridoma using humanized as well as
knockout mouse models.

LEARN MORE

IR NEWS

IR News
March 30, 2022

NEW BIOTECH STARTUPS : INITIUM THERAPEUTICS

Initium Therapeutics was established to develop innovative antibody-based therapeutics, including pursuing new therapeutic targets in fibrosis, immuno-oncology and hemophilia. Initium was established in June of 2020 as a spin-off of South Korea-based Tiumbio in…
IR News
March 30, 2022

THROUGH STRATEGIC COLLABORATION WITH GENSCRIPT PROBIO, INITIUM THERAPEUTICS PLANS TO UTILIZE GENSCRIPT PROBIO’S BERKELEY LIGHTS BEACON PLATFORM TO EXPAND THEIR ANTIBODY DRUG PIPELINE

NANJING, China, Dec. 7, 2020 /PRNewswire/ -- On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio. Initium Therapeutics…

Contact Us

Address

22 Strathmore RD STE 453 Natick MA 01760-2460